Asahi Intecc Co Ltd (JP:7747)
:7747
Want to see JP:7747 full AI Analyst Report?
Top Page
Asahi Intecc Co
(7747)
Select Model
Select Model
Rating:76Outperform
Price Target:
¥4,256.00
▲(21.74% Upside)
Action:Upgraded
Date:05/30/26
The score is driven primarily by strong financial performance (solid growth, strong margins, strong cash conversion, and very low leverage) and supportive technical momentum (price above major moving averages with a positive MACD). These positives are tempered by a relatively expensive valuation (P/E 32.62) and a low dividend yield (0.64%).
Positive Factors
Revenue Growth
Asahi Intecc's recent high revenue growth reflects durable demand for minimally invasive procedures and expanding adoption of its guidewires and interventional products. Consistent top-line expansion supports scale, repeat consumable sales and predictable long-term cash flows for reinvestment.
Negative Factors
Declining Operating Efficiency
A gradual decline in EBIT/EBITDA margins suggests rising cost pressure or mix shifts that could erode operating leverage. If persistent, margin compression would limit the company’s ability to convert revenue growth into higher operating profits and reduce funds available for strategic investments.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Asahi Intecc's recent high revenue growth reflects durable demand for minimally invasive procedures and expanding adoption of its guidewires and interventional products. Consistent top-line expansion supports scale, repeat consumable sales and predictable long-term cash flows for reinvestment.
Read all positive factors
Asahi Intecc Co (7747) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥975.60B
Dividend Yield0.82%
Average Volume (3M)951.34K
Price to Earnings (P/E)32.6
Beta (1Y)0.82
Revenue Growth15.13%
EPS Growth196.11%
CountryJP
Employees9,371
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)46.92
Shares Outstanding265,332,300
10 Day Avg. Volume923,580
30 Day Avg. Volume951,336
Financial Highlights & Ratios
PEG Ratio-2.51
Price to Book (P/B)4.12
Price to Sales (P/S)5.16
P/FCF Ratio19.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥4,200.00Price Target Upside20.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)116.44
Revenue Forecast (FY)¥142.25B
Asahi Intecc Co Business Overview & Revenue Model
Company Description
Asahi Intecc Co., Ltd. engages in the development, manufacture, and sale of medical devices in Japan, the United States, Europe, the Middle East, China, and internationally. The company provides percutaneous transluminal coronary angioplasty (PTCA...
How the Company Makes Money
Asahi Intecc primarily makes money by selling medical-device products and components used in minimally invasive procedures. Key revenue streams include: (1) Guidewires and interventional accessories: Revenue is generated from sales of proprietary ...
Asahi Intecc Co Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
82
Very Positive
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 120.03B | 107.55B | 90.10B | 77.75B | 61.51B |
| Gross Profit | 78.23B | 66.11B | 56.26B | 49.24B | 40.40B |
| EBITDA | 40.23B | 31.86B | 26.73B | 22.61B | 17.76B |
| Net Income | 12.74B | 15.81B | 13.11B | 10.86B | 9.98B |
Balance Sheet | |||||
| Total Assets | 193.19B | 191.61B | 172.64B | 155.13B | 115.43B |
| Cash, Cash Equivalents and Short-Term Investments | 54.20B | 38.66B | 36.88B | 32.32B | 21.36B |
| Total Debt | 11.52B | 8.20B | 15.87B | 13.22B | 9.13B |
| Total Liabilities | 41.83B | 39.65B | 38.34B | 33.99B | 22.48B |
| Stockholders Equity | 150.56B | 151.22B | 132.31B | 119.46B | 92.91B |
Cash Flow | |||||
| Free Cash Flow | 32.45B | 24.83B | 6.85B | 9.32B | -986.00M |
| Operating Cash Flow | 40.54B | 34.71B | 19.14B | 17.30B | 8.92B |
| Investing Cash Flow | -13.43B | -21.22B | -15.13B | -18.70B | -16.33B |
| Financing Cash Flow | -8.11B | -13.88B | -2.34B | 11.37B | 10.11B |
Asahi Intecc Co Technical Analysis
Positive
3496.00
Price Trends
3430.28
Positive
3175.01
Positive
2892.78
Positive
Market Momentum
93.84
Negative
66.92
Neutral
76.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7747, the sentiment is Positive. The current price of 3496 is above the 20-day moving average (MA) of 3486.60, above the 50-day MA of 3430.28, and above the 200-day MA of 2892.78, indicating a bullish trend. The MACD of 93.84 indicates Negative momentum. The RSI at 66.92 is Neutral, neither overbought nor oversold. The STOCH value of 76.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7747.
Asahi Intecc Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ¥975.60B | 32.62 | 11.64% | 0.82% | 15.13% | 196.11% | |
71 Outperform | ¥3.55T | 26.06 | 8.98% | 1.22% | 9.24% | 16.68% | |
71 Outperform | ¥170.73B | 27.28 | ― | 2.73% | 6.29% | -7.19% | |
65 Neutral | ¥2.01T | 28.96 | 11.34% | 1.01% | 1.34% | -40.50% | |
63 Neutral | ¥263.37B | 221.84 | -2.06% | 2.66% | 9.95% | -79.87% | |
54 Neutral | ¥278.49B | 20.79 | 4.38% | 2.03% | 2.47% | 164.11% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:7747
Asahi Intecc Co
3,766.00
1,555.76
70.39%
JP:4543
Terumo
2,401.00
-189.55
-7.32%
JP:7716
Nakanishi
3,050.00
1,211.52
65.90%
JP:8086
Nipro
1,721.00
488.28
39.61%
JP:7733
Olympus
1,785.50
-18.42
-1.02%
JP:7730
Mani, Inc.
1,752.00
591.86
51.02%
Asahi Intecc Co Corporate Events
Asahi Intecc Lifts Sales 18% on Global Medical Demand and Weaker Yen
May 15, 2026
Asahi Intecc reported net sales of 108.37 billion yen for the first nine months of the fiscal year ending June 2026, an 18.0% year-on-year increase, driven by strong demand across its Medical and Device divisions. The Medical Division posted robus...
Asahi Intecc Posts Profit Surge and Hikes Dividend on Strong Nine-Month Results
May 15, 2026
Asahi Intecc reported strong consolidated results for the nine months ended March 31, 2026, with net sales climbing 18.0% year on year to ¥108.37 billion and operating profit jumping 45.5% to ¥37.41 billion. Profit attributable to owners...
Asahi Intecc Secures Exclusive Japan Rights to Nexsphere-F Embolization Agent
Apr 9, 2026
Asahi Intecc has signed an exclusive distribution agreement with South Korea’s NEXTBIOMEDICAL to sell the embolization agent Nexsphere-F in Japan, targeting use in Transcatheter Arterial Micro-Embolization procedures for chronic pain. Althou...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.